Table 2.
Regulation Factor | Research objects | Macrophage polarization | Mechanisms | Year and Country | Reference |
---|---|---|---|---|---|
Alleviating ALI | |||||
Cannabinoid Receptor 2 | Mice, cells | M1→M2 | TLR4 signaling↓; miR-145↓ | 2015, America | (94) |
Protein interacting with C kinase 1 | Mice, cells | M1↓; M2↑ | NF-κB signaling↓; STAT6 signaling↑ | 2016, China | (92) |
P38α deficiency | Mice, cells | M1→M2 | CCL2, CCL5↓; p38α-CREB-C/EBPβ↓ | 2017, China | (100) |
Spermine | Mice, cells | M1↓; M2↑ | STAT1↓, STAT6↑; ATG5↑ | 2018, China | (102) |
Homeobox Containing 1 | Cells, mice | M1↓ | NF-κB signaling↓; MHCII↓ | 2018, China | (104) |
Benzenediamine Analog FC-99 | Mice, cells | M1↓; M2↑ | PPAR-γ signaling↑ | 2019, China | (97) |
p300/CBP inhibitor A-485 | Mice, cells | M1↓ | H3K27ac/H3K18ac↓; NF-κB, MAPK, NLRP3 signaling pathway↓ | 2019, China | (99) |
Human amniotic mesenchymal stromal cells | Mice, cells | M1↓; M2↑ | LC3B-II↑ | 2019, China | (103) |
Carbon monoxide | Mice, cells | M1↓; M2↑ | HIF-1α↓; PI3k/Akt/mTOR signaling↑ | 2021, China | (96) |
Msc-secreted prostaglandin E2 | Mice, cells | M2↑ | STAT6 and mTOR signaling↑ | 2021, China | (93) |
Aggravating ALI | |||||
Hyperglycemia | Mice, cells | M1↑; M2↓ | STAT1↑, STAT6↓; AMPK↓, PI3K/AKT pathway↑ | 2019, China | (95) |
CCL5 | Patient samples, mice | M2 ↓ | MAPK and NF-κB signaling pathway↑ | 2020, China | (98) |